IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New kidney drug enters early human testing
Disease control OngoingThis early-stage study tests a new drug, ARO-CFB, in healthy people and patients with IgA nephropathy, a kidney disease. The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:54 UTC
-
New hope for kidney patients: drug aims to slow IgA nephropathy
Disease control OngoingThis study tests a drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo,…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for kidney patients: experimental drug targets IgA nephropathy in major trial
Disease control OngoingThis phase 3 study tests whether BION-1301 can protect kidney function in adults with IgA nephropathy, a disease where antibodies build up in the kidneys. About 383 participants will receive either the drug or a placebo. The main goal is to see if the drug slows the decline in ki…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for kidney disease: BION-1301 trial underway
Disease control OngoingThis study tests a new medicine called BION-1301 in healthy people and adults with IgA nephropathy, a kidney disease. The goal is to check if the drug is safe and how the body processes it. About 103 participants will be involved in this early-stage trial.
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC